The clinical significance of the expression level of serum adrenergic receptor α1 (ADRA1A) in hysterocarcinoma patients was determined. Peripheral serum samples were collected at the Hubei Cancer Hospital from 455 patients affected by hysterocarcinoma and 380 healthy adults, who served as the normal control group. We determined the expression levels of ADRA1A by ELISA and analyzed its correlation to clinical features and prognosis of the patients. Compared with the normal control group, the expression of ADRA1A in the average peripheral serum level of hysterocarcinoma patients was clearly increased (P<0.05). In addition, the expression level of ADRA1A was positively correlated with the FIGO staging for hysterocarcinoma (r=0.312, P=0.014). Furthermore, the expression levels of serum ADRA1A in patients with metastasis were significantly increased compared to the levels of hysterocarcinoma patients without metastasis (P<0.05). Our analyses also showed that the expression levels of serum ADRA1A in hysterocarcinoma patients did not correlate with patient factors such as age, tumor invasive depth, tumor size or tumor differentiation degree (P>0.05). The Kaplan-Meier survival analysis indicated that the median survival time (37.1 months) of patients with a high expression of serum ADRA1A was lower than that of patients with a low expression of serum ADRA1A (68 months) (P<0.05). The three- and five-year survival rates of patients expressing low serum ADRA1A were, respectively, 74.00 and 62.00%; and the three- and five-year survival rates of patients expressing high levels of serum ADRA1A were 52.00 and 32.00%, respectively, with all the differences being statistically significant (P<0.05). ADRA1A was highly expressed in the peripheral serum in patients with hysterocarcinoma and the expression of ADRA1A was associated with FIGO staging and lymph node metastasis status. The expression of serum ADRA1A can be used to assess the survival rate and may be involved in the pathogenesis and metastasis progression of hysterocarcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958733 | PMC |
| http://dx.doi.org/10.3892/ol.2018.8465 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical significance of expression levels of serum ADRA1A in hysterocarcinoma patients.
Oncol Lett
June 2018
Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, Hubei 430070, P.R. China.
The clinical significance of the expression level of serum adrenergic receptor α1 (ADRA1A) in hysterocarcinoma patients was determined. Peripheral serum samples were collected at the Hubei Cancer Hospital from 455 patients affected by hysterocarcinoma and 380 healthy adults, who served as the normal control group. We determined the expression levels of ADRA1A by ELISA and analyzed its correlation to clinical features and prognosis of the patients.
View Article and Find Full Text PDFThose women diagnosed as having hysterocarcinoma demonstrate even before surgery pronounced immunological disturbances tending to progress after surgical intervention. The employment of cyclopheronum and thymogenum makes for normalization of values for the immune status. Clinically, this is accompanied by a more favourable postoperative course.
View Article and Find Full Text PDFSet out in the paper are results of treatment of those patients with carcinoma of the lung, uterine cervix, hysterocarcinoma, breast cancer, malignant thymomas, malignant non-Hodgkin's lymphomas, and lymphogranulematosis having been administered combined, chemoradiation or radiation treatments against the background of a complex of accompanying therapy involving systemic enzymotherapy. Polyenzymic drugs were found to be capable of improving results of treatment of acute radiation reactions and preventing postradiation fibrous changes in the lungs, skin, fatty tissue, soft tissue, liver, kidneys. Thus, systemic enzymotherapy is capable of improving the quality of life and results of treatment of oncological patients.
View Article and Find Full Text PDFWomen diagnosed as having hysterocarcinoma (HC) demonstrate even prior to surgical intervention manifest abnormalities in metabolic indices, such as increase in the level of medium-size molecules, decrease in the blood content of adenosine triphosphatase, and profound disturbances in microhemodynamics. The most significant abnormalities of metabolism and microcirculation occur in clinical stage III HC against the background of concomitant somatic pathology, diabetes mellitus, arterial hypertension, adiposis in particular.
View Article and Find Full Text PDFIn this paper, consideration is given to the role that etiological and pathogenetic factors have in the development of malignant tumours. Prevention of possible recurrencies and complications in patients with incipient forms of hysterocarcinoma warrant etiotropic treatment which has been shown to be effective and essential for the object to succeed in.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!